معرفی
Ulf Bremberg serves as a Visiting Researcher at Uppsala University's Department of Medicinal Chemistry within the Preparative Medicinal Chemistry division, focusing on synthetic drug development with affiliations at Uppsala Biomedicinska Centrum (BMC).
His research spans Medicinal Chemistry and Drug Design, specializing in synthetic optimization of bioactive compounds targeting serotonin receptors (psilocin derivatives) and angiotensin pathways (AT2R ligands). Key interests include Metabolic Stability Enhancement, Receptor Pharmacology, and Psychedelic Therapeutics Development, with emphasis on improving synthetic accessibility and in vitro performance.
Publications from 2015-2025 reveal consistent innovation in synthesizing receptor-targeted compounds, evolving from enantiopure AT2R antagonists (EMA401) to next-generation psilocin analogs. This trajectory demonstrates expanding expertise from cardiovascular targets toward neuropsychiatric applications, unified by rigorous synthetic methodology and stability profiling.
